Cancer biomarker HER-2/neu in breast cancer in Indian women

QR Code

Cancer biomarker HER-2/neu in breast cancer in Indian women

Rajeev Singhai1, Amit V Patil2, Vinayak W Patil11Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, IndiaAim and objectives: In Indian women with breast cancer, the HER-2/neu...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Singhai R, Patil VW, Patil AV
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2011
Sujets:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/a17f1623757842ac95bcb9d9af75bb38
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
par: Vinayak W Patil, et autres
Publié: (2011)

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women
par: Patil AV, et autres
Publié: (2011)

The p53 breast cancer tissue biomarker in Indian women
par: Patil V, et autres
Publié: (2011)

Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
par: Maral Mokhtari, et autres
Publié: (2021)

Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
par: Matthew M Seavey, et autres
Publié: (2009)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
par: Advani P, et autres
Publié: (2015)

Role of pertuzumab in the treatment of HER2-positive breast cancer
par: Hubalek M, et autres
Publié: (2012)

New developments in the treatment of HER2-positive breast cancer
par: Nahta R
Publié: (2012)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
par: Stenehjem DD, et autres
Publié: (2014)

Triple negative breast cancer: an Indian perspective
par: Akhtar M, et autres
Publié: (2015)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
par: Oostra DR, et autres
Publié: (2014)

Potential of afatinib in the treatment of patients with HER2-positive breast cancer
par: Geuna E, et autres
Publié: (2012)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
par: Moya-Horno I, et autres
Publié: (2015)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
par: Ilana Schlam, et autres
Publié: (2021)

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
par: Hurvitz SA, et autres
Publié: (2012)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
par: G. Griguolo, et autres
Publié: (2021)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
par: Sawaki M
Publié: (2014)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
par: Gaia Griguolo, et autres
Publié: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
par: Federica Miglietta, et autres
Publié: (2021)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
par: Francesco Schettini, et autres
Publié: (2021)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
par: Leticia De Mattos-Arruda, et autres
Publié: (2021)

Tamoxifen for women at high risk of breast cancer
par: Nazarali SA, et autres
Publié: (2014)

De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer
par: Jose G. Bazan, et autres
Publié: (2021)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
par: Natansh D. Modi, et autres
Publié: (2021)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
par: Jamunarani Veeraraghavan, et autres
Publié: (2021)

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
par: Xavier Pivot, et autres
Publié: (2017)

Critical analysis of the potential for microRNA biomarkers in breast cancer management
par: Graveel CR, et autres
Publié: (2015)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
par: Laura M. Spring, et autres
Publié: (2021)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
par: Hanne Vos, et autres
Publié: (2021)

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
par: Merriam PA, et autres
Publié: (2011)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
par: Corey Speers, et autres
Publié: (2017)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
par: Lower EE, et autres
Publié: (2017)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
par: Veronica Giusti, et autres
Publié: (2021)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
par: Salkeni MA, et autres
Publié: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
par: Lize Wang, et autres
Publié: (2021)

Management of early breast cancer in older women: from screening to treatment
par: Elomrani F, et autres
Publié: (2015)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
par: Nina Radosevic-Robin, et autres
Publié: (2021)

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
par: Vogel VG
Publié: (2011)

Allostatic load: a framework to understand breast cancer outcomes in Black women
par: Samilia Obeng-Gyasi, et autres
Publié: (2021)

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study
par: Tom Walsh, et autres
Publié: (2021)